SG Americas Securities LLC acquired a new position in shares of Cardlytics, Inc. (NASDAQ:CDLX – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 14,098 shares of the company’s stock, valued at approximately $45,000.
Several other large investors have also recently bought and sold shares of CDLX. Quadrature Capital Ltd acquired a new stake in shares of Cardlytics during the 1st quarter worth approximately $1,906,000. Vanguard Group Inc. grew its holdings in Cardlytics by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 2,211,595 shares of the company’s stock worth $32,046,000 after acquiring an additional 57,805 shares during the period. Renaissance Technologies LLC grew its holdings in Cardlytics by 711.9% during the 2nd quarter. Renaissance Technologies LLC now owns 351,035 shares of the company’s stock worth $2,882,000 after acquiring an additional 307,800 shares during the period. Susquehanna Fundamental Investments LLC lifted its stake in shares of Cardlytics by 13.8% in the 1st quarter. Susquehanna Fundamental Investments LLC now owns 31,536 shares of the company’s stock valued at $457,000 after purchasing an additional 3,836 shares during the period. Finally, Bank of New York Mellon Corp lifted its stake in shares of Cardlytics by 15.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 135,924 shares of the company’s stock valued at $1,116,000 after purchasing an additional 18,179 shares during the period. Institutional investors and hedge funds own 68.10% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on the stock. Needham & Company LLC cut shares of Cardlytics from a “buy” rating to a “hold” rating in a report on Thursday, August 8th. Lake Street Capital cut shares of Cardlytics from a “buy” rating to a “hold” rating and lowered their price objective for the company from $18.00 to $5.00 in a research report on Thursday, August 8th. Bank of America downgraded Cardlytics from a “neutral” rating to an “underperform” rating and dropped their price objective for the stock from $4.00 to $3.50 in a research note on Thursday, August 15th. Northland Capmk cut Cardlytics from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 16th. Finally, Northland Securities lowered Cardlytics from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $7.00 to $5.00 in a research report on Friday, August 16th. One analyst has rated the stock with a sell rating and six have issued a hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $6.92.
Insider Activity
In other Cardlytics news, Director Scott A. Hill bought 40,000 shares of Cardlytics stock in a transaction that occurred on Monday, August 12th. The stock was acquired at an average price of $3.58 per share, for a total transaction of $143,200.00. Following the completion of the acquisition, the director now owns 40,000 shares of the company’s stock, valued at $143,200. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CEO Amit Gupta sold 22,607 shares of Cardlytics stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $3.85, for a total value of $87,036.95. Following the sale, the chief executive officer now owns 178,519 shares of the company’s stock, valued at approximately $687,298.15. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Scott A. Hill bought 40,000 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The shares were bought at an average price of $3.58 per share, for a total transaction of $143,200.00. Following the acquisition, the director now directly owns 40,000 shares of the company’s stock, valued at $143,200. The disclosure for this purchase can be found here. Insiders have sold 43,573 shares of company stock worth $151,612 over the last ninety days. Insiders own 4.40% of the company’s stock.
Cardlytics Price Performance
Shares of NASDAQ CDLX opened at $3.99 on Wednesday. The company has a fifty day moving average price of $3.62 and a 200 day moving average price of $7.07. Cardlytics, Inc. has a 1-year low of $2.89 and a 1-year high of $20.52. The firm has a market cap of $194.64 million, a PE ratio of -0.90 and a beta of 1.67. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 1.01.
Cardlytics (NASDAQ:CDLX – Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.12. Cardlytics had a negative return on equity of 17.96% and a negative net margin of 50.21%. The company had revenue of $69.64 million during the quarter, compared to analysts’ expectations of $75.39 million. During the same period in the prior year, the firm earned ($0.57) earnings per share. Cardlytics’s revenue for the quarter was down 9.2% compared to the same quarter last year. Research analysts predict that Cardlytics, Inc. will post -1.72 earnings per share for the current fiscal year.
About Cardlytics
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
Further Reading
- Five stocks we like better than Cardlytics
- What is MarketRankā¢? How to Use it
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- What is Forex and How Does it Work?
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- How to Buy Cheap Stocks Step by Step
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
Want to see what other hedge funds are holding CDLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardlytics, Inc. (NASDAQ:CDLX – Free Report).
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.